Sildenafil (Viagra) is NOT recommended for routine use in chronic systolic heart failure
Sildenafil should not be used routinely in patients with chronic systolic heart failure (HFrEF), as the most recent high-quality evidence shows no benefit on mortality, morbidity, or quality of life outcomes. While earlier small studies suggested potential benefits, the definitive RELAX trial demonstrated no improvement in exercise capacity or clinical status, and even showed concerning reductions in left ventricular contractility 1, 2.
Critical Safety Consideration: Absolute Contraindication with Nitrates
Nitrates and sildenafil must NEVER be co-administered. The FDA drug label explicitly states that nitrates should not be given within 24 hours of sildenafil use due to severe, potentially fatal hypotension 3, 4. This is particularly relevant in heart failure patients who may require nitrate therapy for acute decompensation or angina.
Evidence Analysis
Why Sildenafil Fails in Heart Failure
The 2017 ACC/AHA Heart Failure guidelines specifically address this question based on the RELAX trial, which randomized 216 patients with heart failure (EF ≥50%) to sildenafil versus placebo and found no improvement in oxygen consumption or exercise tolerance 1.
More concerning, the RELAX ancillary study (n=48) revealed that sildenafil:
- Reduced left ventricular contractility by 11-16% (peak power index decreased by 52±70 mm Hg/s versus 0±40 with placebo, P=0.006) 2
- Had opposing effects on ventricular versus vascular function
- Any beneficial vascular effects were offset by deleterious cardiac effects
The most recent multicenter trial (SilHF, 2022) in patients with HFrEF and pulmonary hypertension (PASP ≥40 mmHg) confirmed these findings: sildenafil did not improve symptoms, quality of life, PASP, or walk test distance compared to placebo 5. Additionally, the sildenafil group had numerically more serious adverse events (33% vs 21%).
Conflicting Earlier Evidence
Earlier smaller studies (2007-2011) suggested benefits:
- Lewis et al. (2007, n=34) showed improved peak VO2 (+1.8 mL/kg/min) and 6-minute walk distance 6
- Guazzi et al. (2011, n=45) reported improved LV diastolic function and reverse remodeling 7
However, these studies were small, single-center, and have been superseded by larger, more rigorous trials showing no benefit.
Hemodynamic Effects to Consider
The FDA label documents that sildenafil causes:
- Mean decrease in systolic/diastolic BP of 8.3/5.3 mmHg 4
- Reductions in pulmonary artery pressure (28%), cardiac output (7%), and right atrial pressure (28%) in patients with stable ischemic heart disease 4
- Larger hypotensive effects when combined with nitrates (absolute contraindication) 4
These hemodynamic changes can be particularly problematic in heart failure patients with borderline blood pressure or those requiring preload-dependent cardiac output.
Guideline Recommendations
The 2016 ESC Heart Failure Guidelines do not recommend phosphodiesterase-5 inhibitors for heart failure treatment 8. The 2002-2005 ESC guidelines focus on ACE inhibitors, beta-blockers, aldosterone antagonists, and diuretics as evidence-based therapies—sildenafil is notably absent 9, 10.
When Sildenafil Might Be Considered (Erectile Dysfunction Context Only)
If a stable HFrEF patient has erectile dysfunction and specifically requests treatment:
Prerequisites:
- NYHA Class II-III only (stable, compensated)
- No nitrate use (absolute contraindication)
- No recent decompensation
- Systolic BP >100 mmHg
- Negative stress test (no active ischemia)
Dosing (if used for ED, not HF treatment):
- Start 25 mg (lower dose due to hemodynamic sensitivity) 4
- Monitor BP for 4 hours after first dose 11
- Maximum 50 mg if tolerated
One small study (n=35) showed sildenafil 50 mg was safe for erectile dysfunction in NYHA II-III patients without causing symptomatic hypotension, and improved depression scores 11. However, this does not translate to treating heart failure itself.
Common Pitfalls to Avoid
- Do not prescribe sildenafil to "treat" heart failure or pulmonary hypertension secondary to left heart disease—the evidence does not support this
- Never combine with nitrates—check medication lists carefully
- Do not use in decompensated or NYHA IV patients—hemodynamic instability risk
- Avoid in patients with low blood pressure (<100 mmHg systolic)
- Do not extrapolate pulmonary arterial hypertension data to HF-related PH—these are different disease processes
Bottom Line
Sildenafil has no role in the treatment of chronic systolic heart failure. Standard guideline-directed medical therapy (ACE inhibitors/ARBs, beta-blockers, aldosterone antagonists, diuretics) remains the evidence-based approach 9, 10, 8. If considering sildenafil solely for erectile dysfunction in a stable HF patient, ensure absolute contraindications are absent and use the lowest effective dose with careful monitoring.